BeOne Medicines AG (ONC)
Nasdaq · Healthcare · Biotechnology
$361.65+1.00%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $41.1B
- P/E (trailing)
- 64.7
- Forward P/E
- 35.3
- 52-week range
- $253.95 – $385.22
- 52-week change
- +3.93%
- EPS (trailing)
- $5.59
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $5.3B (+40.23%)
- Net income
- $287M
- Operating margin
- 8.4%
- Diluted EPS
- $0.19
- Free cash flow
- $942M
From the company’s annual report on SEC EDGAR.
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Headquarters: Basel, Switzerland · 12,000 employees · beonemedicines.com